Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

39P - Determination of essential biomarkers in lung cancer: A real-world data study in Spain

Date

03 Apr 2022

Session

Poster Display session

Topics

Non-Small Cell Lung Cancer

Presenters

Virginia Calvo de Juan

Citation

Annals of Oncology (2022) 33 (suppl_2): S27-S70. 10.1016/annonc/annonc856

Authors

V. Calvo de Juan1, M. Cobo Dols2, D. Rodriguez-Abreu3, E. Carcereny4, A. Cantero5, R. Bernabe Caro6, G. Benitez Lopez7, R. Lopez Castro8, B. Massuti Sureda9, E. del Barco10, M.R. Garcia Campelo11, M. Guirado12, C.J.C. Camps Herrero13, A.L.O. Ortega Granados14, J.L. Gonzalez-Larriba15, A. Sanchez Hernandez16, C. Gonzalez Ojea17, M.A. Sala Gonzalez18, O.J. Juan Vidal19, M. Provencio Pulla1

Author affiliations

  • 1 University Hospital Puerta de Hierro Majadahonda, Majadahonda/ES
  • 2 Biomedical Research Institute of Málaga (IBIMA), Malaga/ES
  • 3 Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria/ES
  • 4 ICO - Institut Català d'Oncologia Badalona, Badalona/ES
  • 5 Hospital Regional Universitario Málaga Carlos Haya, 29010 - Malaga/ES
  • 6 Hospital Universitario Virgen del Rocio, 41013 - Sevilla/ES
  • 7 Complejo Hospitalario Universitario Insular-Materno Infantil, 35016 - Las Palmas de Gran Canaria/ES
  • 8 Hospital Clinico Universitario De Valladolid, 47003 - Valladolid/ES
  • 9 Hospital General Universitario de Alicante, Alicante/ES
  • 10 Hosp. Clinico Unversitario Salamanca, Salamanca/ES
  • 11 Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña/ES
  • 12 Hospital General Universitario de Elche, 3203 - Elche/ES
  • 13 Hospital General Universitario Valencia, 46014 - Valencia/ES
  • 14 Hospital Universitario de Jaén, Jaén/ES
  • 15 Hospital Clinico Universitario San Carlos, Madrid/ES
  • 16 Consorcio Hospitalario Provincial de Castellón, Castellon de la Plana/ES
  • 17 Hospital Universitario Alvaro Cunqueiro, Vigo/ES
  • 18 Hospital Universitario de Basurto, Bilbao/ES
  • 19 Hospital Universitari i Politècnic La Fe, Valencia/ES
More

Abstract 39P

Background

The Thoracic Tumours Registry (TTR) is an observational, prospective, registry-based study that included patients diagnosed with lung cancer and other thoracic tumours, from September 2016 to date. This TTR study was sponsored by the Spanish Lung Cancer Group (GECP) Foundation, an independent, scientific, multidisciplinary oncology society that coordinates more than 550 experts and 182 hospitals across the Spanish territory.

Methods

To study the situation of biomarker testing in Spain.

Results

9,239 patients diagnosed with stage IV non-small cell lung cancer (NSCLC) were analysed. 7,467 (80.8%) were non-squamous and 1,772 (19.2%) were squamous. Tumour marker testing was performed in 85.0% of patients with non-squamous tumours vs 56.3% in those with squamous tumours (p-value <0.001). The global testing of EGFR, ALK, and ROS1 was 78.9%, 64.7%, 35.6% respectively, in non-squamous histology. PDL1 was determined globally in the same period (46.9%), although if we focus on the last 3 years it exceeds 85%. There has been a significant increase in the last few years of all determinations and there are even close to 10% of molecular determinations that do not yet have targeted drug approval but will have it in the near future. 4,115 cases had a positive result (44.5%) for either EGFR, ALK, KRAS, BRAF, ROS1, or PDL1.

Conclusions

Despite the lack of a national project and standard protocol in Spain that regulates the determination of biomarkers, the situation is similar to other European countries. Given the growing number of different determinations and their high positivity, national strategies are urgently needed to implement next-generation sequencing NGS in an integrated and cost-effective way in lung cancer.

Clinical trial identification

NCT02941458.

Legal entity responsible for the study

FUNDACION GECP.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.